MX353677B - Formulaciones liposomales mejoradas de compuestos lipofilicos. - Google Patents

Formulaciones liposomales mejoradas de compuestos lipofilicos.

Info

Publication number
MX353677B
MX353677B MX2012013528A MX2012013528A MX353677B MX 353677 B MX353677 B MX 353677B MX 2012013528 A MX2012013528 A MX 2012013528A MX 2012013528 A MX2012013528 A MX 2012013528A MX 353677 B MX353677 B MX 353677B
Authority
MX
Mexico
Prior art keywords
cosmetic
liposomal formulations
liposome dispersions
lipophilic compounds
preparation
Prior art date
Application number
MX2012013528A
Other languages
English (en)
Other versions
MX2012013528A (es
Inventor
Hass Heinrich
Fattler Ursula
Original Assignee
Syncore Biotechnology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syncore Biotechnology Co Ltd filed Critical Syncore Biotechnology Co Ltd
Publication of MX2012013528A publication Critical patent/MX2012013528A/es
Publication of MX353677B publication Critical patent/MX353677B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1277—Processes for preparing; Proliposomes
    • A61K9/1278—Post-loading, e.g. by ion or pH gradient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)

Abstract

La presente invención se refiere a la preparación de liposomas con capacidad mejorada de carga para agentes farmacéutica y/o diagnósticamente activos y/o agentes cosméticos, los cuales son substancialmente solubilizados por las membranas liposomales, a dispersiones liposomales con estabilidad mejorada con respecto a la liberación del agente activo y/o agente cosmético desde los liposomas obtenibles a través del procedimiento, y a composiciones farmacéuticas o cosméticas que comprenden dichas dispersiones liposomales estabilizadas. La preparación puede involucrar pasos de deshidratación y rehidratación de las dispersiones liposomales, los cuales se llevan a cabo a través de secado por aspersión.
MX2012013528A 2010-05-21 2011-05-20 Formulaciones liposomales mejoradas de compuestos lipofilicos. MX353677B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US34722210P 2010-05-21 2010-05-21
EP10163643A EP2394640A1 (en) 2010-05-21 2010-05-21 Improved liposomal formulations of lipophilic compounds
PCT/EP2011/058275 WO2011144745A2 (en) 2010-05-21 2011-05-20 Improved liposomal formulations of lipophilic compounds

Publications (2)

Publication Number Publication Date
MX2012013528A MX2012013528A (es) 2013-04-03
MX353677B true MX353677B (es) 2018-01-23

Family

ID=42752328

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012013528A MX353677B (es) 2010-05-21 2011-05-20 Formulaciones liposomales mejoradas de compuestos lipofilicos.

Country Status (18)

Country Link
US (1) US10413511B2 (es)
EP (2) EP2394640A1 (es)
JP (1) JP5966168B2 (es)
KR (2) KR20130085368A (es)
CN (1) CN103002876B (es)
AU (1) AU2011254553B2 (es)
BR (1) BR112012029628B8 (es)
CA (1) CA2796806C (es)
ES (1) ES2640563T3 (es)
HU (1) HUE036459T2 (es)
IL (1) IL222406A0 (es)
MX (1) MX353677B (es)
MY (1) MY162921A (es)
PL (1) PL2571492T3 (es)
RU (1) RU2641605C2 (es)
SG (1) SG184794A1 (es)
WO (1) WO2011144745A2 (es)
ZA (1) ZA201206557B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103181897B (zh) * 2011-12-30 2015-06-10 沈阳药科大学 吉非替尼脂质体制剂及其制备方法
EP2874605A1 (en) * 2012-07-18 2015-05-27 Onyx Therapeutics, Inc. Liposomal compositions of epoxyketone-based proteasome inhibitors
US9993427B2 (en) 2013-03-14 2018-06-12 Biorest Ltd. Liposome formulation and manufacture
PT3138555T (pt) 2014-04-30 2020-12-15 Fujifilm Corp Composição lipossómica e método de produção da mesma
JP6276847B2 (ja) * 2014-04-30 2018-02-07 富士フイルム株式会社 リポソーム組成物及びその製造方法
WO2015166985A1 (ja) * 2014-04-30 2015-11-05 富士フイルム株式会社 リポソーム組成物及びその製造方法
MX2017014130A (es) 2015-05-04 2018-07-06 Versantis AG Metodo para preparar vesiculas con gradiente de ph de transmembrana.
US11304898B2 (en) * 2015-06-09 2022-04-19 Sun Pharma Advanced Research Company Ltd Method of treating carcinoma
SG10201912568PA (en) 2015-10-16 2020-02-27 Ipsen Biopharm Ltd Stabilizing camptothecin pharmaceutical compositions
DK3372232T3 (da) * 2015-11-02 2021-06-07 Fujifilm Corp Tumorterapeutisk middel omfattende gemcitabinliposomsammensætning og kit
EP3377043A4 (en) * 2015-11-20 2019-06-26 The Regents of The University of California DEVICABLE NANOSCAL CARRIER (DNVS) FOR ADMINISTRATION THROUGH THE BLOOD-BRAIN-BARRIER, MICE AND SKIN
WO2018031980A1 (en) * 2016-08-12 2018-02-15 L.E.A.F. Holdings Group Llc Polyglutamated antifolates and uses thereof
JP2019524885A (ja) 2016-08-12 2019-09-05 エル．イー．エー．エフ． ホールディングス グループ エルエルシーＬ．Ｅ．Ａ．Ｆ． Ｈｏｌｄｉｎｇｓ Ｇｒｏｕｐ Ｌｌｃ ポリグルタミン酸化抗葉酸剤およびその使用
BR112019003160A2 (pt) * 2016-08-18 2019-05-28 Bremer Troy composição farmacêutica, métodos para distribuir ureia na interface vitreorretiniana, para induzir desprendimento vítreo posterior e para tratar retinopatia diabética ou adesão vitreomacular, e, uso da composição farmacêutica.
BE1024189B1 (nl) * 2016-10-28 2017-12-05 Yun NV Spuitbus met bacteriële species
US11260028B2 (en) * 2017-06-26 2022-03-01 Fordoz Pharma Corp. Nanosome formulations of aprepitant and methods and applications thereof
KR102072439B1 (ko) * 2018-01-29 2020-02-03 한국과학기술연구원 친환경 용매를 이용한 리포좀 제조방법
WO2019157138A1 (en) 2018-02-07 2019-08-15 L.E.A.F. Holdings Group Llc Alpha polyglutamated pemetrexed and uses thereof
CA3090387A1 (en) 2018-02-07 2019-08-15 L.E.A.F. Holdings Group Llc Alpha polyglutamated pralatrexate and uses thereof
CA3090875A1 (en) 2018-02-14 2019-08-22 L.E.A.F. Holdings Group Llc Gamma polyglutamated lometrexol and uses thereof
TW202042780A (zh) * 2019-01-30 2020-12-01 德商巴地斯顏料化工廠 供個人護理應用之液晶脂質顆粒之化妝品組合物
JP2019218392A (ja) * 2019-08-30 2019-12-26 ズリ・ホールディングス・リミテッドＺｕｌｉ Ｈｏｌｄｉｎｇｓ Ｌｔｄ リポソーム、およびリポソームを含む処方剤
CN112891308A (zh) * 2019-12-04 2021-06-04 杏国新药股份有限公司 脂质体制剂
WO2021221167A1 (ja) * 2020-04-30 2021-11-04 国立大学法人 長崎大学 ガン治療薬及びガン治療方法
CN117568255B (zh) * 2024-01-17 2024-04-30 南京邮电大学 一种细胞膜表面张力调控方法

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH621479A5 (es) 1977-08-05 1981-02-13 Battelle Memorial Institute
FR2416008A1 (fr) 1978-02-02 1979-08-31 Oreal Lyophilisats de liposomes
US4880635B1 (en) 1984-08-08 1996-07-02 Liposome Company Dehydrated liposomes
CA1256372A (en) 1985-04-11 1989-06-27 Koichiro Miyazima Process for producing liposome composition
JPS63500175A (ja) 1985-05-22 1988-01-21 リポソ−ム　テクノロジ−，インコ−ポレイテツド リポソ−ム吸入法および吸入システム
US5089181A (en) 1987-02-24 1992-02-18 Vestar, Inc. Method of dehydrating vesicle preparations for long term storage
JP2931981B2 (ja) 1988-03-04 1999-08-09 武田薬品工業株式会社 リポソーム製剤およびその製造法
ATE77051T1 (de) 1988-03-04 1992-06-15 Takeda Chemical Industries Ltd Liposom-zusammensetzung.
US5049392A (en) * 1989-01-18 1991-09-17 The Liposome Company, Inc. Osmotically dependent vesicles
IT1254135B (it) 1992-01-16 1995-09-08 Sigma Tau Ind Farmaceuti Esteri di acil carnitine con alcooli alifatici a lunga catena e composizioni farmaceutiche che li contengono, ad attivita' antibatterica.
ATE194767T1 (de) * 1992-03-23 2000-08-15 Univ Georgetown In liposomen verkapseltes taxol und verwendungsverfahren
US5837448A (en) * 1992-05-15 1998-11-17 The Salk Institute For Biological Studies Protein-tyrosine kinase genes
AU6833994A (en) * 1993-05-17 1994-12-12 Liposome Company, Inc., The Incorporation of taxol into liposomes and gels
US5993850A (en) * 1994-09-13 1999-11-30 Skyepharma Inc. Preparation of multivesicular liposomes for controlled release of encapsulated biologically active substances
JP3026271U (ja) 1995-12-25 1996-07-02 株式会社ノガミボーリングサービス 残ピン自動検出機能付きボウリングゲーム装置
US6106858A (en) 1997-09-08 2000-08-22 Skyepharma, Inc. Modulation of drug loading in multivescular liposomes
DK1196144T3 (da) * 1999-07-16 2005-01-31 Alza Corp Liposomsammensætning med modstandsevne overfor skader ved frysning/optöning
ES2272496T3 (es) * 2000-02-04 2007-05-01 Lipoxen Technologies Limited Procedimiento de deshidratacion/rehidritacion para la preparacion de lipososmas.
EP1393719A1 (en) * 2002-08-23 2004-03-03 Munich Biotech AG Camptothecin-carboxylate formulations
DE60329497D1 (de) 2002-06-26 2009-11-12 Medigene Ag Herstellung einer kationisch liposomalen zubereitung, einen lipophilen wirkstoff enthaltend
WO2004007492A1 (en) 2002-07-15 2004-01-22 Gesellschaft Fuer Biotechnolgische Forschung Mbh (Gbf) Novel macrocycles for the treatment of cancer
DK1567524T3 (da) 2002-11-28 2009-11-16 Wolfgang Richter Thia-epothilonderivater til behandling af cancer
BRPI0407096A (pt) 2003-02-03 2006-01-24 Neopharm Inc Taxano encapsulado em lipossomo estável, estéril e filtrável e outros fármacos antineoplásicos
CN100427064C (zh) * 2003-04-16 2008-10-22 沈阳药科大学 一种制备脂质体的新方法
CA2530224A1 (en) * 2003-07-09 2005-02-24 California Pacific Medical Center Remote detection of substance delivery to cells
DE10344882A1 (de) 2003-09-26 2005-04-21 Morphochem Ag Komb Chemie Neue Makrocyclen zur Behandlung von Krebserkrankungen
DK2286794T3 (en) 2003-10-15 2016-07-25 Syncore Biotechnology Co Ltd USE OF CATIONIC LIPOSOMES, WHICH INCLUDES paclitaxel
DE10355223A1 (de) 2003-11-26 2005-06-30 Institut für Pflanzenbiochemie (IPB) Neue Makrocyclen zur Behandlung von Krebserkrankungen
DE602005018043D1 (de) * 2004-05-17 2010-01-14 Tekmira Pharmaceuticals Corp Liposomale formulierungen mit dihydrosphingomyelin und verfahren zu ihrer verwendung
CA2582005A1 (en) * 2004-09-13 2006-03-23 Gilead Sciences, Inc. Delivering iron to an animal
AU2005302255A1 (en) * 2004-10-28 2006-05-11 Alza Corporation Lyophilized liposome formulations and method
WO2006055903A1 (en) * 2004-11-18 2006-05-26 Celator Pharmaceuticals, Inc. Method for loading multiple agents into delivery vehicles
CA2601067A1 (en) 2005-05-04 2006-11-09 Medigene Ag Method of administering a cationic liposomal preparation comprising paclitaxel
WO2007005754A2 (en) 2005-07-01 2007-01-11 Alza Corporation Liposomal delivery vehicle for hydrophobic drugs
CN101267805A (zh) 2005-07-27 2008-09-17 普洛体维生物治疗公司 制造脂质体的系统和方法
EP1795184A1 (en) * 2005-12-09 2007-06-13 Ludwig-Maximilians-Universität München Preparation of powders containing colloidal particles
ES2609388T3 (es) 2006-03-22 2017-04-20 Syncore Biotechnology Co., Ltd Tratamiento del cáncer de mama triple negativo a receptores
EP1920765A1 (en) * 2006-11-07 2008-05-14 Medigene AG Liposome preparation by single-pass process
CN101444514B (zh) 2008-12-29 2011-07-06 海南灵康制药有限公司 一种注射用头孢甲肟脂质体制剂及其制备方法
DK177529B1 (en) * 2009-10-23 2013-09-08 Bio Bedst Aps Liposomes with improved storage stability
EP2531175A2 (en) * 2010-02-01 2012-12-12 Yissum Research Development Company of the Hebrew University of Jerusalem, Ltd. Liposomes comprising amphipathic drugs and method for their preparation

Also Published As

Publication number Publication date
MY162921A (en) 2017-07-31
CN103002876B (zh) 2015-12-02
KR20180091102A (ko) 2018-08-14
EP2394640A1 (en) 2011-12-14
ES2640563T3 (es) 2017-11-03
EP2571492A2 (en) 2013-03-27
RU2641605C2 (ru) 2018-01-18
US20130259922A1 (en) 2013-10-03
PL2571492T3 (pl) 2017-12-29
BR112012029628B8 (pt) 2022-09-20
KR101984454B1 (ko) 2019-05-30
MX2012013528A (es) 2013-04-03
IL222406A0 (en) 2012-12-31
AU2011254553B2 (en) 2015-02-05
CN103002876A (zh) 2013-03-27
CA2796806A1 (en) 2011-11-24
WO2011144745A3 (en) 2012-03-01
ZA201206557B (en) 2013-05-29
RU2012155697A (ru) 2014-06-27
KR20130085368A (ko) 2013-07-29
US10413511B2 (en) 2019-09-17
CA2796806C (en) 2019-07-16
HUE036459T2 (hu) 2018-07-30
AU2011254553A1 (en) 2012-12-20
SG184794A1 (en) 2012-11-29
JP5966168B2 (ja) 2016-08-10
JP2013526563A (ja) 2013-06-24
BR112012029628B1 (pt) 2022-08-30
EP2571492B1 (en) 2017-07-26
WO2011144745A2 (en) 2011-11-24
BR112012029628A2 (pt) 2017-07-04

Similar Documents

Publication Publication Date Title
MX353677B (es) Formulaciones liposomales mejoradas de compuestos lipofilicos.
WO2010009277A3 (en) Immunogenic amphipathic peptide compositions
BR112012030653A2 (pt) composição tópica em aerosol, estável ao armazenamento e substancialmente anidra, e, recipiente pressurizado
WO2012151247A3 (en) FORMULATION FOR ANTI-α4β7 ANTIBODY
WO2012021715A3 (en) Stable formulations of linaclotide
WO2012066488A3 (en) Bridged spiro[2.4]heptane ester derivatives
EP3329965A3 (en) Dosing regimen of anti-alpha4beta7-antikörper
EA200870219A1 (ru) Стабилизированные сукцинатом витамина е фармацевтические композиции, способы их получения и применения
WO2011146583A3 (en) Nanoparticulate cinacalcet formulations
WO2012161497A3 (ko) 보습능이 우수한 펩타이드 유도체 및 이의 용도
WO2013087548A3 (en) Loundry compositions
WO2012053013A3 (en) Pharmaceutical compositions of anti-acne agents
WO2013006743A3 (en) Personal care compositions with improved solubility of a solid cosmetic active substance
WO2014118808A3 (en) Ticagrelor solid dispersion
WO2012053009A3 (en) Pharmaceutical compositions comprising nano size droplets of skin whitening agents
MX2014002780A (es) Composiciones farmaceuticas que comprenden un inhibidor de aromatasa.
WO2014016754A3 (en) Pharmaceutical compositions of proton pump inhibitor
MX2015005762A (es) Producto de comicronizacion que comprende acetato de ulipristal.
WO2012173458A3 (ko) 식물 세포 내에 안정화된 활성 물질 및 그 제조방법
WO2014178789A9 (en) Topical composition and carrier for administration of pharmaceutically or cosmetically active ingredients
CL2007003160A1 (es) Compuestos derivados de piridina; procedimiento de preparacion; formulacion farmaceutica; y uso en el tratamiento de enfermedades tales como trombosis, fibrosis renal, isquemia, entre otras.
WO2011139249A3 (en) Pharmaceutical composition comprising cefdinir
MX2017004476A (es) Composicion que comprende al menos un polvo seco obtenido por secado por atomizacion para aumentar la estabilidad de la formulacion.
WO2013024307A3 (en) Branched addition copolymers and their use
WO2012157973A3 (ko) 전분 용기용 조성물, 이를 이용한 전분 용기 및 그 제조방법

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: SYNCORE BIOTECHNOLOGY CO., LTD.

FG Grant or registration